other material
confidence high
sentiment neutral
materiality 0.50
Sigyn corrects prior error; debenture conversion adds 118,700 shares, 9.1% share increase
Sigyn Therapeutics, Inc.
- Corrected prior error: sellers were not controlled by an executive officer.
- $474,793 of convertible debentures converted at $4.00/share for 118,700 shares.
- Shares issued with Rule 144 legend, exempt under Section 4(a)(2).
- Outstanding common shares increased from 1,301,978 to 1,420,678.